Table 1.

Phase II trials of bevacizumab in gynecologic cancers

Study	Therapy	# of patients	Selection Criteria	SD (%)	PR (%)	CR (%)	Median PFS (months) / Median OS (months)
Monk et al.30	Bev	46	Recur CxCa	N/A	10.9	0	3.40/7.29
Burger et al.19	Bev	62	Recur OvCa	51.6	17.7	3.2	4.7/16.9
Cannistra et al.20	Bev	44	Ovaca	61.4	15.9	0	4.4/10.7
Aghajanian et al.29	Bev	52	Recur EndoCa	N/A	1.9	11.5	4.2/10.6
Micha et al.24	CPB/PTX+ bev	20	OvaCa	5	50	30	N/A / N/A
Penson et al.22	CPB/PTX + bev	62	OvCa	21	55	21	29.8/ N/A
Garcia et al.21	Cyclo + bev	70	Recur OvCa	63	24	0	7.2/16.9
Konner et al.25	IV/IP PTX + IP CDDP + bev	41	OvCa	N/A	N/A	N/A	28.6/ N/A

Abbreviations: bev - bevacizumab; CPB - carboplatin PTX - paclitaxel, CDDP- cisplatin, cyclo-cyclophosphamide, OvaCa - epithelial ovarian cancer, CxCa - cervical cancer, EndoCa -endometrial cancer, Recur - recurrent disease, IV – intravenous, IP - intraperitoneal